Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.69 |
| ▸ | MMP1 | P03956 | 5/20 | 0.61 |
| ▸ | MMP2 | P08253 | 5/20 | 0.61 |
| ▸ | MMP9 | P14780 | 5/20 | 0.61 |
| ▸ | MMP8 | P22894 | 5/20 | 0.61 |
| ▸ | MMP13 | P45452 | 5/20 | 0.61 |
| ▸ | BCL2 | P10415 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184499 | 0.90 | ACLY (0.78) | ACLYMMP1MMP2MMP9MMP8 | |
| SCHEMBL15164062 | 0.89 | ACLY (0.88) | ACLYMMP1MMP2MMP9MMP8 | |
| SCHEMBL185182 | 0.87 | ACLY (0.74) | ACLYMMP1MMP2MMP9MMP8 | |
| SCHEMBL184889 | 0.87 | ACLY (0.77) | ACLYMMP1MMP2MMP9MMP8 | |
| SCHEMBL184765 | 0.86 | ACLY (0.73) | ACLYMMP1MMP2MMP9MMP8 | |
| SCHEMBL185275 | 0.85 | ACLY (0.70) | ACLYMMP1MMP2MMP9MMP8 | |
| SCHEMBL184463 | 0.84 | ACLY (0.71) | ACLYMMP1MMP2MMP9MMP8 | |
| SCHEMBL184568 | 0.84 | ACLY (0.69) | ACLYMMP1MMP2MMP9MMP8 | |
| SCHEMBL15164045 | 0.83 | ACLY (0.68) | ACLYMMP1MMP2MMP9MMP8 | |
| SCHEMBL184816 | 0.83 | ACLY (0.67) | ACLYMMP1MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2297103-B1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| EP-2297103-A1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009152082-A1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | ACLY 4026/4885MMP1 2770/4885MMP2 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.